PMID- 37762907 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231003 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 12 IP - 18 DP - 2023 Sep 14 TI - Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study. LID - 10.3390/jcm12185966 [doi] LID - 5966 AB - BACKGROUND: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy and the safety of cemiplimab in a real-world clinical setting. METHODS: A retrospective analysis was carried out for all patients who received at least two doses of cemiplimab at our department between February 2020 and January 2023. Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR) and adverse events (AEs) were evaluated. RESULTS: Twenty-five patients were included with a median age of 78 (65-82) years. The median treatment duration was 48 (16-72) weeks. Five (20%) patients were immunocompromised. Sixteen patients (64%) developed AEs, including 36% serious AEs (SAEs) of grade >/= 3. Six patients (24%) were withdrawn from treatment due to the occurrence of AEs. Among the 25 patients, 52% showed an objective response (3 complete and 10 partial responses), 76% had controlled disease and 24% experienced progression. Among the five immunocompromised patients, the ORR was 60%, while the DCR was 80%. CONCLUSIONS: This retrospective real-world study revealed that locally advanced or metastatic cSCC could be effectively treated with cemiplimab even in elderly, polymorbid and immunocompromised patients. FAU - Kuzmanovszki, Daniella AU - Kuzmanovszki D AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Kiss, Norbert AU - Kiss N AUID- ORCID: 0000-0002-9947-1755 AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Toth, Bela AU - Toth B AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Toth, Veronika AU - Toth V AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Szakonyi, Jozsef AU - Szakonyi J AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Lorincz, Kende AU - Lorincz K AUID- ORCID: 0000-0002-1861-1008 AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Harsing, Judit AU - Harsing J AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Kuroli, Eniko AU - Kuroli E AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Imredi, Eleonora AU - Imredi E AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Kerner, Tunde AU - Kerner T AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Patyanik, Mihaly AU - Patyanik M AD - Uzsoki Street Hospital, Practice Hospital of the Faculty of General Medicine, Semmelweis University, H-1145 Budapest, Hungary. FAU - Wikonkal, Norbert M AU - Wikonkal NM AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. AD - Central Hospital of Northern Pest-Military Hospital, H-1139 Budapest, Hungary. FAU - Szabo, Akos AU - Szabo A AUID- ORCID: 0000-0003-2386-4525 AD - Department of Health Policy, Corvinus University of Budapest, H-1093 Budapest, Hungary. AD - Karoly Racz Doctoral School of Clinical Medicine, Semmelweis University, H-1085 Budapest, Hungary. FAU - Brodszky, Valentin AU - Brodszky V AUID- ORCID: 0000-0002-6095-2295 AD - Department of Health Policy, Corvinus University of Budapest, H-1093 Budapest, Hungary. FAU - Rencz, Fanni AU - Rencz F AD - Department of Health Policy, Corvinus University of Budapest, H-1093 Budapest, Hungary. FAU - Hollo, Peter AU - Hollo P AD - Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary. LA - eng GR - UNKP-23-4-II-SE-8/New National Excellence Program of the Ministry For Innovation and Technology from the source of the National Research, Development and Innovation Fund/ PT - Journal Article DEP - 20230914 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10531652 OTO - NOTNLM OT - PD-1 inhibitor OT - adverse event OT - cemiplimab OT - cutaneous squamous cell carcinoma OT - immune checkpoint inhibitor OT - immunocompromised patients OT - immunotherapy COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/09/28 06:42 MHDA- 2023/09/28 06:43 PMCR- 2023/09/14 CRDT- 2023/09/28 01:23 PHST- 2023/08/30 00:00 [received] PHST- 2023/09/08 00:00 [revised] PHST- 2023/09/12 00:00 [accepted] PHST- 2023/09/28 06:43 [medline] PHST- 2023/09/28 06:42 [pubmed] PHST- 2023/09/28 01:23 [entrez] PHST- 2023/09/14 00:00 [pmc-release] AID - jcm12185966 [pii] AID - jcm-12-05966 [pii] AID - 10.3390/jcm12185966 [doi] PST - epublish SO - J Clin Med. 2023 Sep 14;12(18):5966. doi: 10.3390/jcm12185966.